Bannerbild German Brest Group

Login

 
 

News

  • 28.02.2018 Paper of the month: February 2018

    The first results of the BrighTNess trial designed to evaluate the addition of veliparib (a PARP inhibitor) plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) have been published in the The Lancet Oncology.

    Mehr ...
  • 02.02.2018 Informationsvideo für Patienten

    Prof. Loibl, Leiterin der GBG und Prof. Jackisch, Chefarzt am Sana Klinikum Offenbach sprechen mit einer Patientin über ihre Erfahrungen in einer klinischen Studie.

    Mehr ...
  • 31.01.2018 Paper of the month: January 2018

    A collaborative translational study that included data from six neoadjuvant GBG trials (GeparDuo, GeparTrio, GeparQuattro, GeparQuinto, GeparSixto and GeparSepto) and investigated the role of tumour-infiltrating lymphocytes (TILs) as a prognostic factor in different subtypes of breast cancer after neoadjuvant therapy has been published in the The Lancet Oncology.

    Mehr ...
  • 22.01.2018 JCO top-cited

    Unser Paper über PIK3CA-Mutationen ist eines der meistzitierten Paper in JCO.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd